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Growth and Gene Expression Are Predominantly
Controlled by Distinct Regions
of the Human IL-4 Receptor
John J. Ryan,* Lisa J. McReynolds,* cytokines, while increasing antigen-presenting func-
tions (reviewed by de Waal Malefyt et al., 1993; ZurawskiAchsah Keegan,² Lu-Hai Wang,³ Evan Garfein,§
Paul Rothman,§ Keats Nelms,* and de Vries, 1994).
IL-4 exerts its functions by binding to the IL-4 receptorand William E. Paul*
*Laboratory of Immunology (IL-4R) (Ohara and Paul, 1987; Park et al., 1987; Lowen-
thal et al., 1988) in association with the IL-2Rg chain,National Institute of Allergy and Infectious Diseases
National Institutes of Health now denoted gc (Russell et al., 1994; Miyazaki et al.,
1994). The IL-4R (sometimes designated the IL-4R aBethesda, Maryland 20892-1892
chain) is a widely expressed 140 kDa transmembrane²Holland Laboratory
protein composed of 825 aa, with a 553 aa cytosolicAmerican Red Cross
region (Idzerda et al., 1990; Galizzi et al., 1990). The IL-Rockville, Maryland 20855
4R bears the paired extracellular cysteine residues and³Department of Microbiology
the WSXWS motifcharacteristic of type Icytokine recep-Mount Sinai School of Medicine
tors. Like other members of this family, IL-4R has noNew York, New York 10029-6574
endogenous kinase activity (Cosman, 1993).§Departments of Medicine and Microbiology
Despite the lack of kinase sequences in the IL-4R,Columbia University
multiple substrates are rapidly tyrosine phosphorylatedCollege of Physicians and Surgeons
in response to IL-4 binding. Among these substratesNew York, New York 10032
are the IL-4R itself (Wang et al., 1992; Izuhara et al.,
1993), and a 170 kDa signaling molecule termed 4PS
(Morla et al., 1988; Isfort and Ihle, 1990; Wang et al.,Summary
1992). 4PS has been shown to be antigenically related
to IRS-1, a major substrate of the human insulin receptorIL-4 causes hematopoietic cells to proliferate and ex-
(HIR) and the human insulin-like growth factor-1 recep-press a series of genes, including CD23. We examined
tor (IGF-1R) (Sun et al., 1991; Wang et al., 1993). More-whether IL-4-mediated growth, as measured by 4PS
over, insulin and IGF-1 induce the tyrosine phosphoryla-phosphorylation, and gene induction were similarly
tion of 4PS in myeloid cell lines, while IRS-1 can servecontrolled. Studies of M12.4.1 cells expressing human
as a substrate for IL-4-induced tyrosine phosphorylationIL-4R truncation mutants indicated that the region be-
in transfected 32D-IRS-1 cells and in L cells (Wang ettween amino acids 557±657 is necessary for full gene
al., 1993).expression, which correlated with Stat6 DNA binding
A region of the human IL-4R required for tyrosineactivity. This region was not required for 4PS phos-
phosphorylation of IRS-1 has been delineated (Keeganphorylation. Tyrosine-to-phenylalanine mutations in
et al., 1994). This region included an area of homologythe interval between amino acids 557±657 revealed
found in the IL-4R, HIR, and IGF-1R, termed the I4Rthat as long as one tyrosine remained unmutated,
motif. Expression of IRS-1 in 32D cells, which normally
CD23 was fully induced. When all three tyrosines were
proliferate only weakly to IL-4, insulin, or IGF-1 stimula-
mutated, the receptor was unable to induce CD23.
tion, led to vigorous proliferative responses to each of
The results indicate that growth regulation and gene
these factors. Mutation of the central tyrosine (Y497,
expression are principally controlled by distinct re- numbering from the first translated amino acid) within
gions of IL-4R. the I4R motif blocked IRS-1 tyrosine phosphorylation
and, in most lines tested, IL-4-induced proliferation as
well. These results demonstrate a major role of the IRS-
Introduction 1/4PS signaling pathway in IL-4-mediated proliferation,
and indicate that components of this pathway are
Interleukin-4 (IL-4) is a pleiotropic cytokine produced by shared by IL-4R, HIR, and IGF-1R.
T cells (Howard et al., 1982), mast cells (Brown et al., IL-4 has also been shown to induce DNA binding fac-
1987), and basophils (Seder et al., 1991). It stimulates tors (Kotanides and Reich, 1993; Schindler et al., 1994).
proliferation of activated B cells (Howard et al., 1982) Together with recent evidence indicating an association
and T cells (Mosmann et al., 1986) and of mast cells of the Janus family tyrosine kinases Jak1 and Jak3 with
(Mosmann et al., 1986), as well as inducing or increasing IL-4R (Yin et al., 1994; Russell et al., 1994), these data
the degree of expression of major histocompatibility led to speculation that one or more signal transducers
complex (MHC) class II antigens (Noelle et al., 1984) and and activators of transcription (STATs) may mediate IL-
CD23 (Conrad et al., 1987) on B cells. IL-4 also causes 4-directed gene expression, as has been shown for in-
transcription of unrearranged constant regions for im- terferon-mediated gene expression and gene expres-
munoglobulin E (IgE) (Ie) and IgG1 (Ig1), leading to immu- sion in other type I cytokine systems (for review see
noglobulin class switching and production of IgE and Darnell et al., 1994). Indeed, Stat6 was recently purified
IgG1 (reviewed by Coffman et al., 1993). IL-4 down- from lysates of IL-4-stimulated Thp-1 cells, using the
interferon g (IFNg) activation sequence (GAS), derivedregulates macrophage production of proinflammatory
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Figure 1. Cytokine and Growth Factor Re-
ceptors Expressed in M12.4.1 Cells
Double lines indicate cell membrane; striped
box delineates I4R region. Amino acid num-
ber of Y residues in human IL-4R are shown,
with number designations used in this report.
from the FcgRI promoter, in DNA affinity chromatogra- analysis (Figure 2) or 125I±IL-4 binding (see below). Stimu-
phy (Hou et al., 1994). Phosphopeptides corresponding lation of these transfectants with mouse IL-4 led to tyro-
to two tyrosine-containing regions (Y603 and Y631) of sine phosphorylation of an 185 kDa protein, consistent
the IL-4R blocked the DNA binding activity of Stat6. with the 4PS substrate, as detected by immunoprecipi-
In this study, we examine the requirements for IL-4- tation and Western blotting analysis. Stimulation with
induced gene activation using mouse M12.4.1 lym- the ligands (insulin [4 mg/ml], IGF-1 [500 ng/ml], or hu-
phoma cells expressing deletional and site-directed man IL-4 [20 ng/ml]) specific for the transfected receptor
mutants of the human IL-4R, as well as wild-type HIR also caused phosphorylation of this substrate (Figure
or IGF-1R. We have assessed 4PS tyrosine phosphoryla- 3A). Since M12.4.1 cells lack mRNA for IRS-1 (data not
tion as a measure of growth-related responses, and the shown), these results indicate that HIR and IGF-1R can
IL-4-induced expression of CD23, Ie, and the MHC class activate 4PS in M12.4.1 cells
II antigen I-Ad, as well as the stimulation of Stat6 binding Since both HIR and IGF-1R could activate the 4PS
to a GAS element. Our results show that the region pathway used by the IL-4R, we sought to determine
including amino acids 557±657 of IL-4R,containing three whether IL-4-responsive genes could be induced by in-
Y residues, is essential for full gene induction, but is sulin and IGF-1 in M12.4.1 cells expressing the comple-
dispensable for 4PS phosphorylation. We further dem- mentary receptors. The low affinity receptor for IgE,
onstrate that full gene activation can be obtained as
long as any one of the three Y residues within the amino
acids 557±657 region is not mutated to F. A region of
homology exists around the essential Y residues that
may prove to define a Stat6 interaction site.
A mutant IL-4R truncated at position 557, thus exclud-
ing the three Y-containing sequences in the full-length
IL-4R shown to be required for full gene induction activ-
ity retains partial Stat6 activation potential and induces
diminished expression of CD23, I-Ad, and Ie, suggesting
that Y497, the only Y in the truncated receptor, may be
part of a weak Stat6 binding site. While HIR and IGF-
1R, both of which contain the I4R motif, induce 4PS
tyrosine phosphorylation, neither receptor could convey
expression of CD23, Ie, or I-Ad. We conclude that the
human IL-4R has distinct domains that have predomi-
nant roles in growth stimulation and in gene induction;
possession of the I4R motif alone, although allowing
4PS/IRS-1 phosphorylation, is not sufficient for full IL-
4-induced gene expression.
Results
HIR and IGF-1R Induce 4PS Phosphorylation,
But Not IL-4-Responsive
Gene Expression
IL-4R, HIR, and IGF-1R each induce IRS-1 phosphoryla-
tion in transfected 32D-IRS-1 cells when exposed to
their cognate ligands (Wang et al., 1993). To assess the
ability of insulin and IGF-1 to mimic IL-4-induced gene
activation, we prepared stable transfectants of the
Figure 2. FACScan Analysis of Receptor Expression in M12.4.1M12.4.1 murine B lymphoma line using full-length
TransfectantscDNAs encoding either HIR or the human IGF-1R (Figure
Cells were stained for human IL-4R, HIR, or IGF-1R expression as1). We also prepared transfectants expressing the hu-
described in Experimental Procedures and analyzed by FACScan.man IL-4R as a control for these experiments. Since IL-4
Background fluorescence (control) was determined by staining withis not species cross-reactive, the responses to human
normal rabbit serum (human IL-4R) or 2.4G2 (HIR and IGF-1R) and
and mouse IL-4 could be assessed independently. FITC-conjugated secondary antibodies. Control cell population
Transfectants were selected that expressed detect- staining is indistinguishable from background staining. Results are
from three separate experiments.able surface receptors, as demonstrated by FACScan
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CD23, was strongly induced on M12.4.1 cells and each
of the transfectants by stimulation with mouse IL-4 (Fig-
ure 3B). Neither insulin (0.1±100 mg/ml) nor IGF-1 (0.5±
500 ng/ml) inducedCD23 expression oncells expressing
HIR or IGF-1R, respectively (Figure 3B). Similarly, HIR
and IGF-1R failed to up-regulate the expression of the
MHC class II antigen I-Ad, an effect that was induced
by mouse IL-4 (Figure 3C). These results were further
corroborated by study of another IL-4-responsive gene,
the germline form of the IgE constant region (Ie). IL-4
stimulation of M12.4.1 cells results in Ie expression, as
detected by Northern blot analysis (Figure 3D). However,
neither HIR- nor IGF-1R-expressing clones induce Ie
mRNA in response to their cognate ligands, although
these clones did show striking induction in response to
mouse IL-4.
Transfectants expressing human IL-4R showed in-
duction of CD23, MHC class II, and Ie in response to
human IL-4, comparable in magnitude to induction by
mouse IL-4 through the endogenous mouse IL-4R (Fig-
ure 3). Thus, HIR and IGF-1R failed to mimic the effects
of IL-4 in gene expression assays. These findings indi-
cate that possession of an I4R motif is insufficient for
IL-4-induced gene expression.
Characterization of Human IL-4R Deletion
Mutants Delineates a Region Required
for Full Gene Induction
We previously used a series of deletion mutants of the
human IL-4R to identify the receptor region necessary
for tyrosine phosphorylation of IRS-1. These studies,
using the 32D-IRS-1 cell line, demonstrated that termi-
nation of the receptor at amino acid 437 (D437) resulted
in a complete loss of 4PS phosphorylation, while dele-
tion at amino acid 557 (D557) left this pathway intact
(Keegan et al., 1994). These studies demonstrated the
essential role played by the I4R motif (contained in resi-
dues 437±557) in IRS-1 activation. In this work, we have
used these receptor deletion mutants in the M12.4.1 cell
line to ascertain which receptor domain is required for
IL-4-induced gene activation and to confirm that re-
quirements for IRS-1 phosphorylation extend to 4PS
phosphorylation in M.12.4.1. cells.
M12.4.1 stable transfectants expressing various dele-
tion mutations of the human IL-4R (see Figure 1) were
prepared and screened by FACScan analysis, 125I±IL-4
binding analysis, or both. As expected, 4PS phosphory-
lation was induced by human IL-4 stimulation of M12.4.1
cells bearing D557, but not by those expressing D437
human IL-4R, or by mock-transfected cells (Figure 4A),
confirming the importance of the region between amino
Figure 3. Receptors for Insulin and IGF-1 Can Phosphorylate 4PS, CD23expression and I-Ad up-regulation in M12.4.1 transfectants.
but Fail to Induce IL-4-Activated Genes Cells were stimulated with 500 U/ml mouse IL-4, 1 ng/ml human IL-
4, 50 ng/ml IGF-1, 5 mg/ml insulin, or were left unstimulated for 48(A) Human IL-4R (WT4R), IGF-1R, and HIR induce 4PS phosphoryla-
tion. Cells were stimulated with 10,000 U/ml mouse IL-4, 20 ng/ml hr and assessed for CD23 (B) or I-Ad (C) expression by FACScan
analysis as described.human IL-4, 50 ng/ml IGF-1, or 5 mg/ml insulin for 10 min, lysed,
and subjected to immunoprecipitation and Western blotting using (D) Cells were stimulated with 10 mg/ml lipopolysaccharide alone
or in combination with 500 U/ml mouse IL-4, 20 ng/ml human IL-4,4G10 anti-phosphotyrosine antibodies as described. Expected size
of 4PS band is indicated, as are molecular size markers. Results 50 ng/ml IGF-1, or 5 mg/ml insulin for 48 hr and assessed for Ie
expression by Northern blot analysis as described. Arrowhead indi-with IGF-1R and HIR are from two separate experiments.
(B±C) Human IL-4R (WT4R), but not IGF-1R or HIR can induce cates expected size of Ie band.
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Figure 4. Human IL-4R Deletion Mutants De-
lineate Regions Required for 4PS Phosphory-
lation and Gene Expression
(A) 4PS phosphorylation is not affected by
deletion of human IL-4R at amino acid 557,
but is blocked by deletion at amino acid 437.
Human IL-4R transfectants or neomycin-re-
sistant control cells (neo) were stimulated
with 10,000 U/ml mouse IL-4 or 20 ng/ml hu-
man IL-4 for 10 min, lysed, and subjected
to immunoprecipitation and Western blotting
using 4G10 anti-phosphotyrosine antibodies
as described. Expected size of 4PS band is
indicated, as are molecular size markers.
(B±C) Full human IL-4-induced CD23 expres-
sion and I-Ad up-regulation require residues
between amino acids 557±657. M12.4.1
transfectants expressing the indicated hu-
man IL-4R mutants were stimulated and assessed for CD23 or I-Ad expression by FACScan analysis as described.
(D) Analysis of Ie expression in M12.4.1 transfectants expressing human IL-4R deletions. Cells were stimulated with 10 mg/ml lipopolysaccharide
alone or in combination with 500 U/ml mouse IL-4 or 20 ng/ml human IL-4 for 48 hr and assessed for Ie expression by Northern blot analysis
as described. Arrowhead indicates expected size of Ie band. Low amount of Ie induction by mouse IL-4-stimulated D437 cells was due to
clonal variability, and was not observed in other D437 populations.
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acids 437±557, containing the I4R motif, in 4PS acti-
vation.
We next assessed human IL-4-induced gene expres-
sion in these deletion mutants. M12.4.1 cells bearing
the wild-type or D657 human IL-4R were fully capable
of expressing CD23 in response to human IL-4 (Figure
4B). However, the D557 mutant showed strikingly dimin-
ished CD23 induction, suggesting an important role for
amino acids 557±657 in gene expression. The D437 mu-
tant completely failed to induce CD23, indicating that
the minimal induction observed inD557-expressing cells
required residues between amino acids 437±557, the
region containing the I4R motif.
The results obtained with the study of CD23 induction
were confirmed by assessment of I-Ad and Ie induction.
In response to human IL-4 stimulation, both wild-type
and D657 mutants were capable of increasing the levels
of I-Ad on M12.4.1 transfectants, while we were unable
to detect such an increase in D557 and D437 mutants
(Figure 4C). Ie was fully induced by wild-type and D657
mutants in response to human IL-4, as compared with
the responsiveness to mouse IL-4. Stimulation of D557-
bearing cells gave Ie levels that were no more than 20%±
30% of the responsiveness to endogenous mouse IL-
4R as determined by densitometric analysis (data not
shown). D437 mutants failed to induce any detectable
Ie mRNA in response to human IL-4 (Figure 4D). The
phosphorylation of 4PS and induction of CD23, I-Ad, and
Ie in response to human IL-4 were studied in three or
more individual clones for each of these mutant recep-
tors, with similar results. Therefore, the region of human
IL-4R between amino acids 557±657 appears to be es-
sential for full IL-4-induced gene expression, but is not
necessary for 4PS phosphorylation.
Recent findings have resulted in the identification of
the signal-transducing and transcription molecule,
Stat6, induced by IL-4 (Hou et al., 1994). Stat6 has been Figure 5. EMSA and Supershift Analysis of Human IL-4R Deletion
Mutantsshown to bind phosphopeptides corresponding to se-
Cells were stimulated for 10 min with 10,000 U/ml mouse IL-4 or 20quences in the IL-4R including Y603 and Y631 (Hou et
ng/ml human IL-4, lysed, and 5 mg of cleared lysates were incubatedal., 1994), which are, of course, included in the 557±657
with 32P-labeled GAS oligonucleotide, then were subjected to (A)interval that appears essential for full IL-4-mediated in-
PAGE or (B) were incubated with rabbit anti-mouse Stat6 or control
duction of CD23, MHC class II, and Ie. To examine Stat6 rabbit serum prior to PAGE as described.
activation by the various IL-4R deletion mutants, we
performed electrophoretic mobilityshift analysis (EMSA)
with control sera. This result argues strongly that Stat6and antibody-mediated supershifting. M12.4.1 cells
is activated following stimulation through the D657 andbearing wild-type or mutated human IL-4R were stimu-
D557 IL-4R mutants. Our observations with the D557lated with human or mouse IL-4, and lysates were as-
and D437 mutants suggest that a degree of Stat6 activa-sessed for their ability to bind a labeled DNA sequence
tion can be mediated by sequences within residues 437±corresponding to a GAS element in the b-casein pro-
557 of IL-4R, but that full activity requires amino acidsmoter. As shown in Figure 5A, gel-retarded complexes
557±657.were formed by human IL-4-stimulated lysates from
wild-type, D657, and to some extent, D557 mutants in
Site-Directed Mutagenesis of Human IL-4Rresponse to human IL-4. D437 and mock transfectants
Indicates an Essential Role of Tyrosinedid not induce detectable complexes (Figure 5A). Ly-
Residues Between Amino Acids 557±657sates from D557 transfectantsactivated with human IL-4
in IL-4-Induced Gene Expressiongave a protein±DNA complex that was about 20%±30%
Our data indicated that full Stat6 activation and IL-4of that induced by mouse IL-4, while cells expressing
gene induction rely upon amino acids 557±657 of thewild-type and D657 mutants showed responses to
human IL-4R. We wished to determine which, if any, ofmouse and human IL-4 that were essentially equivalent.
the three Y residues in the 557±657 region are requiredTo ascertain whether the protein±DNA complex con-
for IL-4-induced gene expression. We used site-directedtained Stat6, we performed supershift analysis using
mutagenesis to induce Y to F changes at positions 575anti-Stat6 sera. As shown in Figure 5B, all IL-4-induced
complexes could be shifted with this antisera, but not (Y2F), 603 (Y3F), Y631 (Y4F), and all combinations of
Immunity
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Figure 7. Human IL-4 Receptor Number Versus CD23 Expression
Cells were analyzed for receptor number by 125I±IL-4 binding, and
for CD23 expression by FACScan analysis as described. Each data
point represents an individual clone. Results are means of duplicate
samples from 1±9 separate experiments. CD23 positive indicates a
human IL-4-induced increase in CD23 expression that was similar
to mouse IL-4 responsiveness, with the exception of D557 mutants
(as shown in Figure 4). Transfectants used in figures are denoted
with the figure number in parentheses. Clones screened for human
IL-4R expression by FACSCan analysis or 125I±IL-4 binding gave
identical results in all experiments. Some clones shown in the rele-
vent figures (e.g., D557 and D437) were screened by FACScan analy-
sis, and 125I±IL-4 binding results were not determined.
range from 8 pg/ml±1 ng/ml of human IL-4, using at least
two independent transfectants of each type (data not
shown). Thus, any one of the three tyrosines between
amino acids 557±657can bemutated without an obvious
defect in gene expression.
We next examined cells expressing receptors that
carried two Y mutations in the human IL-4R (Y2,3F,
Y2,4F, Y3,4F). Our results again showed these mutant
receptors to be active for CD23 expression (Figure 6B).
As shown in Figure 7, among the Y to F mutants capable
of inducing CD23, a positive response depended upon
expression of 2500 receptors per cell or more. The posi-
tive transfectants showed no notable difference in dose
response analysis with human IL-4 (data not shown).
The capacity of the Y3,4F mutant to induce CD23 wasFigure 6. Site-Directed Mutagenesis of Human IL-4R Indicates that
somewhat surprising, since it lacks both Ys includedTyrosines Between Amino Acids 557±657 Are Required for Human
in the phosphopeptides demonstrated to inhibit Stat6IL-4-Induced CD23 Expression
binding to the FcgRI GAS element (Hou et al., 1994).M12.4.1 transfectants expressing Y to F mutations of one (A), two
(B), or three (C) Y residues were assessed by FACScan analysis for However, extracts from IL-4-stimulated Y3,4F mutants
the ability to induce CD23 in response to human IL-4 as described. form a complex with the b-casein GAS element that is
supershifted by anti-Stat6 (data not shown). This com-
plex was greater in magnitude than that induced by the
557 mutant. These results thus imply that the sequencethese residues (see Figure 1). We focused on CD23 in-
duction as an assay for gene expression, since this re- containing Y2 is a Stat6 site. The failure of Y2,3,4F to
induce CD23 (see Figure 6C) verifies the importance ofsponse has yielded the clearest results, and both I-Ad
and Ie assays have directly correlated to CD23 expres- Y2 in the capacity of Y3,4F to induce CD23. Indeed,
Y2,3,4F mutants showed no response to a broad rangesion in our studies.
Analysis of CD23 induction by M12.4.1 cells express- (8pg/ml±25ng/ml) of human IL-4 concentrations, nor did
extracts from an IL-4-stimulated Y2,3,4F mutant form aing Y2F, Y3F, or Y4F mutations demonstrated that each
of these tyrosines is dispensable (Figure 6A). These complex with the b-casein GAS element (data not
shown). The lines expressing Y2,3,4F mutant receptorstransfectants showed dose response curves for CD23
induction similar to wild-type±expressing cells over the expressed slightly fewer receptors than some mutants,
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but as many receptorsper cell as did some transfectants in substantial diminution of such activation and dimin-
ished, but did not abolish, Stat6 DNA binding. Indeed,that were able to induce CD23 (Figure 7). These results
Quelle et al. (1995) had used some of the 32D-IRS-indicate that any of the three Ys in the amino acids
1-transfected cell lines previously described (Keegan et557±657 interval and their surrounding sequences can
al., 1994) to demonstrate that D657 truncation mutantsmediate CD23 expression, presumably through activa-
efficiently tyrosine phosphorylate Stat6, while D557 andtion of Stat6.
D437 mutants failed to do so. Pernis et al. (1995) hadThe failure of Y2,3,4F to show any induction of CD23
reported generally similar results in that 32D-IRS-1 cellsis somewhat surprising in view of the finding that D557
expressing D657 induced a Stat6-mediated EMSA withinduces CD23 expression, although only to a modest
the GAS element from the b-casein promoter, while cellsdegree. This result could indicate a negative regulatory
expressing D437 failed to do so (Pernis et al., 1995).effect of sequences in the amino acids 557±657 interval,
However, Pernis et al. (1995) observed that 32D-IRS-1which is observable when each of the Ys in that region
cells expressing the D557 truncation mutant do inducehave been mutated to F.
a partial Stat6-mediated EMSA, as we have shown in
D557 M12.4.1 transfectants.
These findings point to a crucial role for sequencesDiscussion
in the interval between amino acids 557 and 657, a region
containing three tyrosine residues, two of which hadIL-4R signaling shares common features with that of
been indicated as likely Stat6 interaction sites (Hou etHIR and IGF-1R. Each of these receptors can use IRS-
al., 1994). This region, completely separate from the I4R1/4PS as a principal signaling substrate (Wang et al.,
motif, appears to define a Stat6 gene activation domain1993; Keegan et al., 1994). A key piece of evidence in
of the IL-4R.establishing the central role of IRS-1 in IL-4-, insulin-,
We have examined the function of this region of theand IGF-1-mediated growth responses was the demon-
receptor by site-directed mutagenesis, inserting Y to Fstration that the 32D myeloid cell line, which lacks IRS-1/
changes to yield every possible combination of Y muta-4PS, fails to proliferate in response to these stimulants.
tions in the domain. Mutation of any single or any twoFurthermore, a 32D cell line transfected with an IRS-1
Ys had no effect on CD23 expression induced by humancDNA (32D-IRS-1) shows striking proliferation in re-
IL-4. Mutation of all three Ys resulted in mutant receptorssponse to each of these factors (Wang et al., 1993).
that no longer induced CD23. We did note a correlationThis system was used to delineate an IRS-1 activation
between CD23 induction and the level of expression ofsequence, termed the I4R motif, that is present in the
the transfected receptor. Wild-type human IL-4R func-IL-4R, HIR, and IGF-1R. Mutation of the Y within this
tioned fully at very low levels (<1000/cell), while mutatedmotif blocked the phosphorylation of IRS-1 and, in most
receptors generally lost functionality at levels belowinstances, blocked the growth response mediated by
2500/cell. This may imply the existence of subtle defectsIL-4. In this study, we have furthered our understanding
in these point mutants.of IL-4R-mediated signaling by examining induced gene
The fact that all double mutants studied were active
expression events in a murine B cell line. M12.4.1
in the CD23 assay, while the triple mutant was not, ar-
transfectants bearing HIR or IGF-1R strikingly phos-
gues that tyrosine 2, 3, or 4 and their surrounding se-
phorylated 4PS in response to ligand binding. However,
quences are individually sufficient to induce CD23 ex-
neither insulin nor IGF-1 induced expression of CD23, pression. Thus, it is likely that each of these is a Stat6
the MHC class II antigen I-Ad, or Ie. By contrast, mouse binding site. We therefore designate the amino acids
IL-4 induced each of these gene products in all cell lines, 557±657 region, with its three tyrosine residues, to be
and human IL-4 did so in lines that expressed the wild- a Stat6/gene activation domain, distinct from the pre-
type human IL-4R. These data show that while posses- viously described domain containing the I4R region,
sion of the I4R motif allows for activation of the growth- which, since it plays an important role in IL-4-mediated
related 4PS pathway, this pathway alone is insufficient cell growth, might be designated a growth domain.
for IL-4-induced gene expression. Hou et al. (1994) found that IL-4R-derived phospho-
Using 4PS phosphorylation as an assay for growth- peptides containing Y3 or Y4 could inhibit Stat6±DNA
related events, we confirmed previous findings from this complex formation in an EMSA assay, while other IL-4R
laboratory (Keegan et al., 1994). As was the case with phosphopeptides, including Y2, could not. There are
32D-IRS-1 cells, termination of the human IL-4R at several explanations for this difference in results. It is
amino acids 657 or 557 had no effect on4PS phosphory- possible that Stat6 has preferential binding for Y3 and
lation, while termination at amino acid 437 resulted in a Y4, but can use Y2, particularly in physiological situa-
complete loss of such phosphorylation. This deletional tions in which signaling may proceed over extended
analysis indicated the importance of residues between periods of time. Indeed, the observation that extracts
amino acids 437±557, the region containing the I4R motif from IL-4-stimulated Y3,4F cells form a Stat6-containing
and its central Y497 (Y1). This data reaffirms the impor- complex with the b-casein GAS element indicates that
tance of the I4R motif and residues between amino acids the Y2 site can activate Stat6. It is also possible that
437±557 of the human IL-4R in 4PS activation, a growth- other signaling molecules either cooperate with or sub-
related signal transduction pathway. stitute for Stat6, and that these molecules can utilize
The requirements for IL-4-induced gene expression the Y2 binding site to induce CD23. It should be pointed
were quite different from those needed for 4PS phos- out that cell lines expressing D557 also induce IL-4-
phorylation. While D657 retained full activity in gene mediated gene expression and Stat6 activation, al-
though only to a minimal extent, strongly suggestingexpression assays, deletion to amino acid 557 resulted
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to signal differentiations clearly demonstrated by Wang
et al. (1995). Nonetheless, it seems likely that within the
context of an intact receptor, domain±domain interac-
tions may occur that regulate and coordinate overall
receptor functions.
Experimental Procedures
Cells/Reagents
The murineB cell line M12.4.1 was the gift of Dr. R. Asofsky (National
Institute of Allergy and Infectious Diseases, Bethesda, Maryland)
and was maintained in RPMI 1640 medium (GIBCO BRL, Grand
Island, New York) supplemented with 10% fetal bovine serum, 2
mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and
1 mM sodium pyruvate, all from Biofluids, Incorporated (Rockville,
Maryland) (cRPMI). Rat anti-human IL-4R, clones M8 and M10, were
donated by Immunex Corporation (Seattle, Washington). Mouse
anti-HIR was purchased from Amersham Life Sciences (Arlington
Heights, Illinois). Mouse anti-IGF-1R was purchased from Oncogene
Science (Uniondale, New York). Phycoerythrin (PE)-conjugated goat
anti-rat IgG, fluorescein isothiocyanate (FITC)-conjugated rat anti-
mouse CD23 (clone B3B4), and FITC-conjugated rat anti-mouse I-Ad
(clone AMS-32.1) were purchased from PharMingen (San Diego,
California). FITC-conjugated rat anti-mouse IgG was purchased
from Southern Biotechnology Associates (Birmingham, Alabama).Figure 8. Description of Signaling Motifs in the Human IL-4R
4G10 anti-phosphotyrosine antibody was purchased from UpstateTop shows Growth and Differentiation domains of human IL-4R,
Biotechnologies, Incorporated (Lake Placid, New York).encoded by amino acids 437±557 and 557±657, respectively.
Bottom shows amino acid sequence of I4R region from HIR or hu-
FACS Analysisman IL-4R, or from Y2, Y3, and Y4 of human IL-4R. Boxed shaded
Cells were first stained with 3 ml 2.4G2 rat anti-mouse FcgRII/IIIareas indicate regions of homology.
ascites, for 10 min at 48C, followed by 10 mg/ml FITC-conjugated
rat anti-mouse CD23 or rat anti-mouse I-Ad for 30 min at 48C in
phosphate-buffered saline, 3% fetal calf serum, 0.1% sodium azide.
that Y1 may also constitute a weak Stat6 binding site. In For HIR or IGF-1R analysis, 2.4G2-stained cells were incubated with
support of this, Wang et al. (1996 [this issue of Immunity]) 10 mg/ml mouse anti-HIR or mouse anti-IGF-1R for 1 hr at 48C,
washed, and stained with 10 mg/ml FITC-conjugated rat anti-mousehave found that a chimeric receptor composed of a
IgG. For IL-4R analysis, cells were first stained with 1l normal rabbittruncated human IL-2Rb and human IL-4R amino acids
serum, then incubated with 1 mg/ml M8 and M10 rat anti-human IL-437±557 signals CD23 induction in M12.4.1 cells, while
4R for 1 hr at 48C, washed, and stained with 10 mg/ml PE-conjugatedsimilar receptors bearing a Y1F mutation of amino acids
mouse anti-rat IgG. Cells were then washed twice and analyzed in
437±557 fail to do so, strongly implicating Y1 in gene the presence of propidium iodide with a Becton-Dickinson FACScan
regulation. (Becton-Dickinson, San Jose, California).
Y3 and Y4 have an extended region of homology,
cDNAs/Expression Vectorsindicated by the consensus sequence GEXGYKXFXXL.
Human insulin receptor cDNA expression vector was the gift of Dr.However, the sequences surrounding each of the four
M. White (Joslin Diabetes Center, Boston, Massachusetts). The IGF-Ys implicated in our work do show homology, although
1R cDNAwas subcloned into the eukaryotic expression vector pMX±
of a more modest degree. A consensus among the four neo, containing a retroviral LTR promoter. Full-length and truncated
would yield be (21 G or A) / 0 Y/(11 K or R or Q) / 12 human IL-4R cDNAs were cloned into the vector pLTR.2 (a gift
X / 13 F (Figure 8). Furthermore, the sequence sur- from Dr. J. Pierce, National Cancer Institute, Bethesda, Maryland),
containing the Rous sarcoma virus (RSV) LTR promoter. Human IL-rounding the I4R motif Y in the HIR and IGF-1R differs
4R cDNAs bearing point mutations in tyrosine residues 575 (2), 603from that of the IL-4R in this region, lacking the G or A
(3), and/or 631 (4) were cloned into the RSV LTR expression vectorat 21, the basic or polar residue at 11, and the F at 13,
pREP.9 (Invitrogen, San Diego, California). Neomycin-resistant con-
consistent with the failure of insulin and IGF-1 to induce trol transfectants were derived by expression of pREP.9 or
CD23 expression in M12.4.1 lines expressing the cog- pMX±neo.
nate receptors. The possibility that a more limited se-
Site-Directed Mutagenesisquence than that defined by Hou et al. (1994) may consti-
Mutagenesis of specific residues in the human IL-4R was carriedtute a physiologic Stat6-binding site is supported to
out using the Promega Altered Sites II in vitro mutagenesis systemsome degree by the demonstration that introduction of
(Promega, Madison, Wisconsin), according to the specifications of
a 5 aa sequence (GYMPQ) conferred Stat3 activation the manufacturer. Oligonucleotides used for mutagenesis are indi-
function to the erythropoietin receptor (Stahl et al., cated, with the mutated codon in italics:
1995). Y2F (Y575 to F), 59 CCC ACC AGT GGC TTT CAG GAG TTT GTA
Y3F (Y603 to F), 59 GGA GAG GCT GGT TTC AAG GCC TTC TCAThe results of this paper indicate that growth and
Y4F (Y631 to F), 59 GGG GAA GAG GGG TTT AAG CCT TTC CAAdifferentiation mediated through the IL-4R are indepen-
dently determined and that principal control sequences
Creation of Stable Transfectantsfor these broad classes of functions are in two indepen-
M12.4.1 cells (5 3 106) were transfected with 20 mg uncut plasmid
dent portions of the IL-4R. This segregation of function, DNA with a Bio-Rad Genepulser electroporation device (Bio-Rad,
while striking, is not complete. The I4R motif found in Melville, New York), using 960 mFD and 200 V. Plasmids containing
the WT4R, D657, D557 receptor cDNA were cotransfected with 2the growth domain appears to have a limited capacity
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mg LTR±neo. Cells were grown in 10 ml cRPMI overnight, then se- antisera; and Dr. M. White, Joslin Diabetes Center, for providing the
HIR cDNA. P. Rothman is supported by National Institutes of Healthlected for resistance to neomycin (G418, GIBCO BRL, Grand Island,
New York) at 800 mg/ml for 12±21 days. Colonies were screened by grant RO1AI33540 and grants from the Pew Scholars Trust and
Pfizer Corporation. J. J. R. is supported inpart by a CancerResearchantibody staining, 125I±IL-4 binding, or both.
Institute/Miriam and Benedict Wolf fellowship.
125I±IL-4 Binding Assay
Received September 6, 1995; revised December 19, 1995.To detect surface expression of human IL-4R, cells (1 3 107/ml)
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Referenceswith 20 ng/ml 125I±IL-4 (provided by Dr. J. Pierce, National Cancer
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